We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
On this page, you will find the most up-to-date notices regarding current events and their impact on West Operations.
Voluntary Field Corrective Action issued for two (2) lots of Vial2Bag Advanced® 20mm Admixture Device
On September 24, 2024, West has issued a voluntary Field Safety Corrective Action, instructing our distributor and end-user facilities to discontinue use and return two (2) lots of Vial2Bag Advanced® 20mm Admixture Devices. Our top priority is the safety of all patients utilizing our products and meeting our commitment to quality.
Click here for the Consignee Letter for more information.
Last Updated on September 25, 2024
Israel - West Pharmaceutical Services, Inc. Update
In response to the ongoing hostilities in Israel, we remain committed to providing transparent and timely communications concerning any impact on our manufacturing operations at our West Israel facilities and our overall supply chain. Our foremost concern is the safety and welfare of our team members, their families, and the local communities in this region. At present, all West sites, suppliers, and partners remain operational with no substantial disruption to our manufacturing and supply chain operations. Our primary logistics lanes for air and sea freight also remain open and fully functional.
To mitigate risks and ensure the continuity of supply, we are accelerating the shipment of all finished goods and critical components out of Israel. Additionally, we are leveraging alternative network warehouse solutions. West team members will reach out if an order is completed earlier than expected to discuss logistics accordingly. Our global crisis team is closely monitoring the evolving situation and remains in constant contact with our suppliers and logistics partners. We are prepared to inform you promptly of any changes that might affect your business operations.
We deeply appreciate the unwavering dedication of our West Israel team and partners who continue to support our customers and the patients they serve during these challenging times.
Thank you for your understanding and cooperation as we navigate these difficulties together. Should you have any specific customer inquiries or concerns, please contact your Account Manager or Customer Success representative.
Last Updated on September 25, 2024
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
English
Chinese
